The use of structural biology in janus kinase targeted drug discovery

Current Drug Targets

Volumn 12, Issue 4, 2011, Pages 546-555

  Alicea Velázquez, Nilda L ^a   Boggon, Titus J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cp 690,550; Crystal structure; Jak kinase; Jak2 v617f; Kinase inhibitor

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AZD 1480; CYT 387; INCB 01842; INCB 018424; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; LESTAURTINIB; PROTEIN KINASE TYK2; TG 101348; UNCLASSIFIED DRUG; VX 509; XL 019;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME STRUCTURE; HUMAN; NONHUMAN; POINT MUTATION; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; JANUS KINASES; MUTATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 79952766751     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011794751528     Document Type: Article

References (83)

1. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol 2004; 5(12): 253.
2. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 2007; 44(10): 2497-506.
3. Ihle JN, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995; 11(2): 69-74.
4. Darnell JJ, Kerr I, Stark G. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264(5164): 1415-21.
5. Girault JA, Labesse G, Mornon JP, Callebaut I. The N-termini of FAK and JAKs contain divergent band 4.1 domains. Trends Biochem Sci 1999; 24(2): 54-7.
6. Usacheva A, Sandoval R, Domanski P, et al. Contribution of the Box 1 and Box 2 motifs of cytokine receptors to Jak1 association and activation. J Biol Chem 2002; 277(50): 48220-6.
7. Haan C, Hermanns HM, Heinrich PC, Behrmann I. A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction. Biochem J 2000; 349(Pt 1): 261-6.
8. Cacalano NA, Migone TS, Bazan F, et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3- receptor interaction domain. EMBO J 1999; 18(6): 1549-58.
9. Chen M, Cheng A, Chen YQ, et al. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci U S A 1997; 94(13): 6910-5.
10. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005; 203: 127-42.
11. Radtke S, Jorissen A, de Leur HS, Heinrich PC, Behrmann I. Three dileucine-like motifs within the interbox1/2 region of the human oncostatin M receptor prevent efficient surface expression in the absence of an associated Janus kinase. J Biol Chem 2006; 281(7):4024-34.
12. Haan C, Heinrich PC, Behrmann I. Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. Biochem J 2002; 361(Pt 1): 105-11.
13. Radtke S, Haan S, Jorissen A, et al. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem 2005; 280(27): 25760-8.
14. Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors--an intimate relationship. Biochem Pharmacol 2006; 72(11): 1538-46.
15. Haan C, Behrmann I, Haan S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med 2010; 14(3): 504-27.
16. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell Biol 2006; 16(9): 443-52.
17. Chen M, Cheng A, Candotti F, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 2000; 20(3): 947-56.
18. Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007; 17(1): 8-14.
19. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002; 277(49): 47954-63.
20. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000; 20(10): 3387-95.
21. Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem 2005; 280(51): 41893-9.
22. Pissot-Soldermann C, Gerspacher M, Furet P, et al. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Bioorg Med Chem Lett 2010; 20(8): 2609-13.
23. Wang T, Duffy J, Wang J, et al. Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem 2009; 52(24): 7938-41.
24. Wang T, Ledeboer M, Duffy J, et al. A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors. Bioorg Med Chem Lett 2010; 20(1): 153-6.
25. Ledeboer M, Pierce A, Duffy J, et al. 2-Aminopyrazolo[1,5- a]pyrimidines as potent and selective inhibitors of JAK2. Bioorg Med Chem Lett 2009; 19(23): 6529-33.
26. Williams NK, Bamert RS, Patel O, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 2009; 387(1): 219-32.
27. Lucet IS, Fantino E, Styles M, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006; 107(1): 176-83.
28. Chrencik JE, Patny A, Leung IK, et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol 2010; 400(3): 413-33.
29. Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009; 52(2): 379-88.
30. Baffert F, Regnier CH, De Pover A, et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP- BSK805. Mol Cancer Ther 2010; 9(7): 1945-55.
31. Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 2005; 106(3): 996-1002.
32. Antonysamy S, Hirst G, Park F, et al. Fragment-based discovery of JAK-2 inhibitors. Bioorg Med Chem Lett 2009; 19(1): 279-82.
33. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002; 109(3): 275-82.
34. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene 2004; 23(48): 7918-7927.
35. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003; 14(4): 1448-59.
36. Zhou YJ, Chen M, Cusack NA, et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell 2001; 8(5): 959-69.
37. Haan S, Margue C, Engrand A, et al. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation- dependent Jak activation. J Immunol 2008; 180(2): 998-1007.
38. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 2008; 19(4): 414-22.
39. Bourdeau A, Dube N, Tremblay ML. Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC- PTP. Curr Opin Cell Biol 2005; 17(2): 203-9.
40. Zhou YJ, Hanson EP, Chen YQ, et al. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc Natl Acad Sci USA 1997; 94(25): 13850-5.
41. Shields BJ, Court NW, Hauser C, Bukczynska PE, Tiganis T. Cell cycle-dependent regulation of SFK, JAK1 and STAT3 signalling by the protein tyrosine phosphatase TCPTP. Cell Cycle 2008; 7(21):3405-16.
42. Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006; 6(8): 671-9.
43. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278(5341): 1309-12.
44. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS- variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9; 12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90(7): 2535-40.
45. Griesinger F, Hennig H, Hillmer F, et al. A BCR-JAK2 fusion gene as the result of a t(9; 22)(p24; q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005; 44(3): 329-33.
46. Bousquet M, Quelen C, De Mas V, et al. The t(8; 9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005; 24(48): 7248-52.
47. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65(7): 2662-7.
48. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365(9464): 1054-61.
49. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7(4): 387-97.
50. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352(17): 1779-90.
51. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434(7037): 1144-8.
52. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280(24): 22788-92.
53. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112(6): 2190-8.
54. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high- risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106(23): 9414-8.
55. Jeong EG, Kim MS, Nam HK, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008; 14(12): 3716-21.
56. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006; 10(1): 65-75.
57. Cornejo MG, Boggon TJ, Mercher T. JAK3: a two-faced player in hematological disorders. Int J Biochem Cell Biol 2009; 41(12):2376-9.
58. Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205(4): 751-8.
59. Notarangelo LD, Mella P, Jones A, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat 2001; 18(4): 255-63.
60. O'Shea JJ, Husa M, Li D, et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 2004; 41(6-7): 727-37.
61. Watford WT, O'Shea JJ. Human tyk2 kinase deficiency: another primary immunodeficiency syndrome. Immunity 2006; 25(5): 695-7.
62. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008; 22(10): 1813-7.
63. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3(7): e270.
64. Suessmuth Y, Elliott J, Percy MJ, et al. A new polycythaemia vera- associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Br J Haematol 2009; 147(4): 450-8.
65. Levinson NM, Kuchment O, Shen K, et al. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol 2006; 4(5): e144.
66. Thompson JE, Cubbon RM, Cummings RT, et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 2002; 12(8): 1219-23.
67. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302(5646): 875-8.
68. Jiang JK, Ghoreschi K, Deflorian F, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4- methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperi din-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 2008; 51(24): 8012-8.
69. Zhang X, Hu Y, Yuan Z. Computational analyses of JAK1 kinase domain: subtle changes in the catalytic cleft influence inhibitor specificity. Biochem Biophys Res Commun 2008; 370(1): 72-6.
70. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21(8): 1658-68.
71. Geron I, Abrahamsson A, Barroga C, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008; 13(4): 321-30.
72. Kiss R, Polgár T, Kirabo A, et al. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett 2009; 19(13): 3598-601.
73. Sudbeck EA, Liu XP, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999; 5(6): 1569-82.
74. Uckun F, Roers B, Waurzyniak B, Liu X, Cetkovic-Cvrlje M. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 2002; 99(11): 4192-9.
75. Schindler T, Bornmann W, Pellicena P, Miller W, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289(5486): 1938-42.
76. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64(18): 6652-9.
77. Zhao L, Dong H, Zhang CC, et al. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J Biol Chem 2009; 284(39): 26988-98.
78. Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001; 14(1): 27-37.
79. Mohammadi M, Schlessinger J, Hubbard SR. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 1996; 86(4): 577-87.
80. Fukuda K, Gupta S, Chen K, Wu C, Qin J. The pseudoactive site of ILK is essential for its binding to alpha-Parvin and localization to focal adhesions. Mol Cell 2009; 36(5): 819-30.
81. Haan C, Kroy DC, Wuller S, et al. An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. J Immunol 2009; 182(5): 2969-77.
82. Waiboci LW, Ahmed CM, Mujtaba MG, et al. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implica- tions for the development of a SOCS-1 antagonist. J Immunol 2007; 178(8): 5058-68.
83. Ahmed CM, Dabelic R, Waiboci LW, Jager LD, Heron LL, Johnson HM. SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system. J Virol 2009; 83(3): 1402-15.